Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.
Hepatocellular Carcinoma|Liver Cancer
DRUG: Sorafenib|RADIATION: Stereotactic Body Radiotherapy (SBRT)
Determine the Safety and Tolerability of Sequential SBRT and Sorafenib in Patients With Unresectable Hepatocellular Carcinoma, Number of subjects experiencing a Grade 5 toxicity related to SBRT and sorafenib, between baseline and 3 years
The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Tumor Volume, mean tumor volume at baseline, 4 weeks and 10 weeks after start of treatment, baseline, 4 weeks and 10 weeks|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Ktrans (Volume Transfer Coefficient)., The initial mean Ktrans at baseline, 4 weeks and 10 week. K trans is used to describe the uptake of gadolinium contrast in tissue., baseline, 4 weeks and 10 weeks|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by Kep. Kep Describes How Fast Contrast Can Redistribute in Tissue., The Kep as measures by MRI at baseline, 4 weeks after baseline, and 10 weeks after baseline., baseline, 4 weeks after baseline and 10 weeks post baseline|The Degree of Change in Necrosis and Vascular Permeability Via Dynamic Contrast Enhanced (DCE) and Diffusion-weighted Imaging (DWI) Magnetic Resonance Imaging (MRI) as Measured by ADC (Apparent Diffusion Coefficient)., the measured ADC at baseline, 4 weeks after baseline and then 10 weeks after baseline. ADC quantifies the motion of water protons from an MRI., baseline, 4 weeks post baseline, 10 weeks post baseline
This study is to determine the safety and efficacy of stereotactic body radiotherapy (SBRT) and treatment drug in patients with hepatocellular carcinoma.